Biocon just scored a major win in Europe—this time for your bones. The biotech giant got the green light from the European Union for two new biosimilars: Vevzuo and Evfraxy, both based on denosumab, a powerful treatment that prevents bone damage.
These approvals aren’t just stamps on paper. They’re proof that Biocon is pushing into new territory: bone health, where big-name drugs often stay out of reach for millions due to sky-high prices.
So, what’s denosumab anyway?
Denosumab is a lab-made antibody. It works by blocking a protein called RANKL, which tells special bone cells (osteoclasts) to break down bone.
When RANKL is blocked, bone stays stronger, longer.
Meet the new duo: Vevzuo and Evfraxy
Vevzuo is approved to:
- Prevent bone complications in adults with advanced cancer that has spread to the bone
- Treat adults and teens with giant cell tumour (GCT) of bone
Evfraxy is for:
- Osteoporosis in postmenopausal women and men
- Bone loss caused by hormone therapy in men with prostate cancer
- Bone damage from long-term steroid use
And yes, both biosimilars match the original drugs in quality, safety, and results. That’s backed by clinical data.
Also Read Biocon Abandons China Plan for Weight-Loss Drugs; 15+ Local Rivals Crowd Market
This isn’t Biocon’s first rodeo
In the past 18 months, Biocon has:
- Secured approvals for three biosimilars in Europe
- Landed two more in the UK
- Continued its mission to make life-saving treatments affordable and global
Shreehas Tambe, Biocon Biologics CEO, summed it up:
“These approvals show our scientific strength and commitment to improving access in new areas like bone health.”
Why this matters
Europe’s stamp of approval isn’t just good news for Biocon—it’s great news for patients.
In a world where many can’t afford the drugs they need, biosimilars like these are hope wrapped in science.
And Biocon? It’s proving that innovation doesn’t have to come with a luxury price tag.
The bigger picture
This isn’t just about medicine. It’s about changing the rules of the game.
Where big pharma locks people out, Biocon is breaking the door open.
In a market driven by profit, Biocon is choosing purpose.
And that’s a story we don’t hear often enough.
Also Read Biocon Eyes Early Lead in Canada’s Generic Wegovy, Ozempic Market
